Stattin P - Search Results

1

Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.

Vellekoop A, Loeb S, Folkvaljon Y, Stattin P. Vellekoop A, et al. Among authors: stattin p. J Urol. 2014 Feb;191(2):350-7. doi: 10.1016/j.juro.2013.09.034. Epub 2013 Sep 23. J Urol. 2014. PMID: 24071481

2

Percent Gleason grade 4/5 as prognostic factor in prostate cancer diagnosed at transurethral resection.

Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P. Egevad L, et al. Among authors: stattin p. J Urol. 2002 Aug;168(2):509-13. J Urol. 2002. PMID: 12131299

3

Population-based study of prostate-specific antigen testing and prostate cancer detection in clinical practice in northern Sweden.

Pilebro B, Johansson R, Damber L, Damber JE, Stattin P. Pilebro B, et al. Among authors: stattin p. Scand J Urol Nephrol. 2003;37(3):210-2. doi: 10.1080/00365590310008064. Scand J Urol Nephrol. 2003. PMID: 12775278

4

MRI of the skeleton in prostate cancer staging.

Rydh A, Lundblad M, Ahlström KR, Tavelin B, Stattin P. Rydh A, et al. Among authors: stattin p. Scand J Urol Nephrol. 2003;37(3):222-5. doi: 10.1080/00365590310008091. Scand J Urol Nephrol. 2003. PMID: 12775281

5

Non-systematic screening for prostate cancer in Sweden--survey from the National Prostate Cancer Registry.

Stattin P, Johansson R, Damber JE, Hellström M, Hugosson J, Lundgren R, Varenhorst E, Johansson JE. Stattin P, et al. Scand J Urol Nephrol. 2003;37(6):461-5. doi: 10.1080/00365590310015778. Scand J Urol Nephrol. 2003. PMID: 14675917

6

High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort.

Stattin P, Rinaldi S, Biessy C, Stenman UH, Hallmans G, Kaaks R. Stattin P, et al. J Clin Oncol. 2004 Aug 1;22(15):3104-12. doi: 10.1200/JCO.2004.10.105. J Clin Oncol. 2004. PMID: 15284261

7

Tumor size, vascular density and proliferation as prognostic markers in GS 6 and GS 7 prostate tumors in patients with long follow-up and non-curative treatment.

Josefsson A, Wikström P, Granfors T, Egevad L, Karlberg L, Stattin P, Bergh A. Josefsson A, et al. Among authors: stattin p. Eur Urol. 2005 Oct;48(4):577-83. doi: 10.1016/j.eururo.2005.05.016. Eur Urol. 2005. PMID: 15990221

8

The National Prostate Cancer Register in Sweden 1998-2002: trends in incidence, treatment and survival.

Varenhorst E, Garmo H, Holmberg L, Adolfsson J, Damber JE, Hellström M, Hugosson J, Lundgren R, Stattin P, Törnblom M, Johansson JE. Varenhorst E, et al. Among authors: stattin p. Scand J Urol Nephrol. 2005;39(2):117-23. doi: 10.1080/00365590510007793. Scand J Urol Nephrol. 2005. PMID: 16019764

9

Geographical variation in incidence of prostate cancer in Sweden.

Stattin P, Johansson R, Lodnert R, Andrén O, Bill-Axelsson A, Bratt O, Damber JE, Hellström M, Hugosson J, Lundgren R, Törnblom M, Varenhorst E, Johansson JE. Stattin P, et al. Scand J Urol Nephrol. 2005;39(5):372-9. doi: 10.1080/00365590500375463. Scand J Urol Nephrol. 2005. PMID: 16257838

10

The magnitude of early castration-induced primary tumour regression in prostate cancer does not predict clinical outcome.

Ohlson N, Bergh A, Nygren K, Stattin P, Wikström P. Ohlson N, et al. Among authors: stattin p. Eur Urol. 2006 Apr;49(4):675-83. doi: 10.1016/j.eururo.2005.10.024. Epub 2005 Dec 19. Eur Urol. 2006. PMID: 16387414

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

522 results

Search Page

Filters